• In late July 2026, Quest Diagnostics introduced self-collection services for bacterial vaginitis and other common genital tract infections across more than 2,000 patient service centers, alongside publishing large-scale study data on co-infection risks and diagnostic value of modern molecular testing.
• At the same time, Quest raised its full-year 2026 revenue and earnings guidance after reporting stronger second quarter sales and net income versus the prior year, underscoring how its expanding advanced diagnostics and health data capabilities may be supporting business momentum.
• We’ll now examine how the upgraded 2026 guidance and expanding molecular self-collection services influence Quest Diagnostics’ broader investment narrative.

Find 51 companies with promising cash flow potential yet trading below their fair value.

Quest Diagnostics Investment Narrative Recap

To own Quest Diagnostics, I think you have to believe in a large, recurring business in advanced diagnostics and health data, supported by consistent volumes and careful cost control. The upgraded 2026 revenue and earnings guidance reinforces near term earnings momentum, while the biggest current risk still looks like reimbursement and payer mix pressure rather than any immediate impact from the self-collection launch, which feels incremental rather than transformational for the story in the short run.

Among recent developments, the raised full year 2026 guidance, following higher second quarter sales and net income, ties most directly into the investment case around stable growth and margin resilience. It connects this new self-collection offering to a broader pattern of expanding molecular and data driven services that appear to support Quest’s ability to absorb industry price pressure and wage inflation while still growing earnings at a measured pace.

Yet behind the strong 2026 guidance and new self collection services, investors still need to watch how potential PAMA reimbursement cuts could...

Quest Diagnostics’ narrative projects $13.3 billion revenue and $1.5 billion earnings by 2029. This requires 4.7% yearly revenue growth and about a $0.4 billion earnings increase from $1.1 billion today.

Uncover how Quest Diagnostics' forecasts yield a $239.38 fair value, in line with its current price.

Exploring Other Perspectives

Two Simply Wall St Community fair value estimates for Quest Diagnostics span roughly US$239 to US$348 per share, showing how widely views can differ. Against that backdrop, the updated 2026 guidance and continued expansion in advanced testing put a sharper focus on whether reimbursement and payer mix risks might cap how much of this optimism ultimately flows through to long term performance.

Explore 2 other fair value estimates on Quest Diagnostics - why the stock might be worth just $239.38!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Quest Diagnostics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Quest Diagnostics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Quest Diagnostics' overall financial health at a glance.

No Opportunity In Quest Diagnostics?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.